Naporafenib, a RAF dimer selective inhibitor, in combination with the MEK inhibitor trametinib or in combination with the ERK inhibitor LTT462, is being explored in a clinical trial for its efficacy in advanced metastatic KRAS- or BRAF-mutant NSCLC or in NRAS-mutant melanoma (NCT02974725, Table 1). This evidence concerns the gene MAP2K7 and melanoma.